BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35798468)

  • 21. [Fluoropyrimidines cardiac toxicity: 5-fluorouracil, capecitabine, compound S-1 and trifluridine/tipiracil].
    Vaflard P; Ederhy S; Torregrosa C; André T; Cohen R; Lopez-Trabada D
    Bull Cancer; 2018; 105(7-8):707-719. PubMed ID: 29960638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.
    Layoun ME; Wickramasinghe CD; Peralta MV; Yang EH
    Curr Oncol Rep; 2016 Jun; 18(6):35. PubMed ID: 27113369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.
    Saneeymehri SS; Markey KR; Mahipal A
    J Oncol Pharm Pract; 2016 Jun; 22(3):552-5. PubMed ID: 25852107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.
    Vater LB; Lefebvre B; Turk A; Clasen SC
    Curr Oncol Rep; 2022 Jul; 24(7):943-950. PubMed ID: 35347593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
    Wu Z; Deng Y
    Curr Treat Options Oncol; 2018 Nov; 19(12):77. PubMed ID: 30483908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk Factors of Fluoropyrimidine Induced Cardiotoxicity among Cancer Patients: A Systematic Review and Meta-analysis.
    Li C; Ngorsuraches S; Chou C; Chen L; Qian J
    Crit Rev Oncol Hematol; 2021 Jun; 162():103346. PubMed ID: 33930532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
    Deboever G; Hiltrop N; Cool M; Lambrecht G
    Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-FU Cardiotoxicity: Vasospasm, Myocarditis, and Sudden Death.
    More LA; Lane S; Asnani A
    Curr Cardiol Rep; 2021 Feb; 23(3):17. PubMed ID: 33537861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-Fluorouracil, capecitabine and vasospasm: a scoping review of pathogenesis, management options and future research considerations.
    Teperikidis E; Boulmpou A; Charalampidis P; Tsavousoglou C; Giannakoulas G; Papadopoulos CE; Vassilikos V
    Acta Cardiol; 2022 Feb; 77(1):1-13. PubMed ID: 33683181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment.
    Molteni LP; Rampinelli I; Cergnul M; Scaglietti U; Paino AM; Noonan DM; Bucci EO; Gottardi O; Albini A
    Breast J; 2010; 16 Suppl 1():S45-8. PubMed ID: 21050310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
    J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
    Kwakman JJ; Simkens LH; Mol L; Kok WE; Koopman M; Punt CJ
    Eur J Cancer; 2017 May; 76():93-99. PubMed ID: 28286287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.
    Polk A; Vaage-Nilsen M; Vistisen K; Nielsen DL
    Cancer Treat Rev; 2013 Dec; 39(8):974-84. PubMed ID: 23582737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An unusual case of acute myopericarditis after the first dose of capecitabine: Need for new cardioprotective strategies and risk stratification.
    Meter M; Gavran I; Bajo D; Duplancic D
    Int J Clin Pharmacol Ther; 2021 Dec; 59(12):775-779. PubMed ID: 34503643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
    Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
    Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.
    Jensen SA; Sørensen JB
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):487-93. PubMed ID: 16418875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluoropyrimidine-associated cardiotoxicity: revisited.
    Saif MW; Shah MM; Shah AR
    Expert Opin Drug Saf; 2009 Mar; 8(2):191-202. PubMed ID: 19309247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of Fluoropyrimidine-Induced Cardiac Adverse Outcomes Following Cancer Treatment.
    Rajaeinejad M; Parhizkar-Roudsari P; Khoshfetrat M; Kazemi-Galougahi MH; Mosaed R; Arjmand R; Mohsenizadeh SA; Arjmand B
    Cardiovasc Toxicol; 2024 Feb; 24(2):184-198. PubMed ID: 38324115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy.
    Li C; Chen L; Chou C; Ngorsuraches S; Qian J
    Cardiovasc Toxicol; 2022 Feb; 22(2):130-140. PubMed ID: 34792740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.